These findings highlight the critical impact of FCRL1 on survival outcomes and therapeutic efficacy, suggesting its potential as a biomarker for tailoring treatment strategies in DLBCL, the most common type of B-NHL (Figure 4 and Figure 5 and Table 6 and Table 7). The gene discussed is FCRL1; the disease is diffuse large B-cell lymphoma.